Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Dynavax Technologies Corporation (NASDAQ: DVAX) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Dynavax Technologies Corporation (NASDAQ: DVAX) concerning whether a series of statements by Dynavax Technologies Corporation regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On September 2, 2016, the U.S. Food and Drug Administration revealed that it had cancelled Dynavax’s November 16, 2016 meeting with the Vaccines and Related Biological Products Advisory Committee in order to allow time to review and resolve outstanding issues with the Company’s Biologics License Application for HEPLISAV-B™.

Following this news, NASDAQ: DVAX dropped $5.03 or 32% from its previous closing price to close at $10.91 on September 2, 2016.

Based in Berkeley, California, and founded in 1996 Dynavax Technologies Corporation discovers and develops novel vaccines and therapeutics in the United States.

If you purchased shares of Dynavax Technologies Corporation (NASDAQ: DVAX) on or before September 2, 2016, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185